What to watch out for on the CAR-T cell therapy front
With ASH starting this week, it’s time for our annual CAR-T cell therapy Preview.
With a storm warning in Britain today, this also seems a rather apt way of summarising the CAR-T cell abstracts!
Just half a dozen years ago you could count the number of CAR-T cell abstracts on the fingers of one hand, now there’s over 300 to choose from.
What stands out this year and what can we learn from a couple of important controversies in this niche?
Ahead of the meeting, we highlight a number of key abstracts and discuss some of the underlying issues we have been following to give readers a heads up on what to watch out for…
BSB subscribers can read up on our ongoing commentary and analysis from the cancer conference season – you can either log-in or click to access our latest analysis.
This content is restricted to subscribers
